The advent of immune checkpoint inhibitors (ICIs) has led to a fundamental shift in the approach to treatment of advanced melanoma, resulting in significant improvement in survival outcomes for these patients.1,2 In particular, anti–programmed cell death protein 1 (anti–PD-1) monotherapies with agents including pembrolizumab or nivolumab are established regimens for advanced melanoma management, as are combination therapies consisting of anti–PD-1 agents and the cytotoxic T-cell lymphocyte antigen 4 blockade-agent ipilimumab.3 Here, PDCD1 is linked to melanoma.